Yiqi Huoxue Decoction in the treatment of Qi and yin deficiency and stasis type diabetic nephropathy in stageⅢ and its effect on VEGF and TGF-β1

Objective:To observe the efficacy of Yiqi Huoxue Decoction in the treatment of patients with diabetic nephropathy(DN)stageⅢwith qi and yin deficiency and stasis and its effects on vascular endothelial growth factor(VEGF)and transforming growth factor-β(TGF-β1).Methods:Sixty patients with stage DN of Qi-yin deficiency and stasis type DN who were treated in the Endocrinology Department of the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from September 2018 to December 2019 were selected as the research subjects.The remainder method was used to divide them into 30 cases in the observation group and 30 cases in the control group.Patients in both groups were referred to the guidelines and expert consensus for general treatment of DN(hypogl-ycemic,antihypertensive,lipid-lowering,etc.).The control group was given pancreatic kallikrein enteric-coated tablets orally once,120U,3 times a day,and the observation group was given The traditional Chinese medicine Yiqi Huoxue Decoction was taken orally,one dose daily,twice a day in the morning and evening;the two groups intervened continuously for 8 weeks.Detect blood FPG,PBG,HbA1c,β2-MG,BUN,SCr,VEGF,TGF-β1,and urine mALB and UACR levels before and after treatment,and calculate eGFR before and after treatment in both groups;observe changes in TCM syndrome scores in the two groups,Compare its clinical efficacy.Results:After 8 weeks of treatment,the total clinical effective rate of patients in the observation group was 93.3%,which was significantly different from the control group of 76.6%(P<0.05);the TCM syndrome scores in the observation group were significantly lower than those before treatment and in the control group(P<0.05);The levels of FPG,HbA1c,PPG,mALB,β2-MG,UACR,VEGF,and TGF-β1 in the observation group were significantly lower than those in the control group,with significant differences(P<0.05).The levels of SCr and BUN in the observation group were significantly lower.Compared with before treatment,eGFR increased,but there was no signi-ficant difference(P>0.05).Conclusion:Yiqi Huoxue Decoction for the treatment of patients with DN typeⅢqi-yin deficiency and stasis type,not only helps to lower blood sugar levels,improve TCM syndromes,but also can reduce early renal damage,reduce urine albumin,and delay kidney function It may be further worsened and has better safety.The mechanism may be related to reducing the levels of VEGF and TGF-β1,thereby delaying the fibrosis of tubulointerstitial scar and inhibi-ting glomerular capillary sclerosis.

Stage Ⅲ should be subclassified into Stage ⅢA and ⅢB in the American Joint Committee on Cancer(8^(th) Edition) staging system for pancreatic cancer

AIM To ascertain the prognostic role of the T4 and N2 category in stage Ⅲ pancreatic cancer according to the 8 th edition of the American Joint Committee on Cancer(AJCC) classification.METHODS Patients were collected from the Surveillance Epidemiology and End Results(SEER) database(2004-2013) and were divided into three groups: T(1-3)N2, T4 N(0-1), and T4 N2. Overall survival(OS) and disease-specific survival(DSS) of patients were evaluated by the Kaplan-Meier method. RESULTS For the first time, we found a significant difference in OS and DSS between T(1-3)N2/T4 N(0-1) and T4 N2 butnot between T(1-3)N2 and T4 N(0-1). A higher grading correlated with a worse prognosis in the T(1-3)N2 and T4 N2 groups.CONCLUSION Patients with stage T4 N2 had a worse prognosis than those with stage T(1-3)N2/T4 N(0-1) in the 8 th edition AJCC staging system for pancreatic cancer. We recommend that stage Ⅲ should be subclassified into stage ⅢA [T(1-3)N2/T4 N(0-1)] and stage ⅢB(T4 N2).

Bushen Huoxue method combined with ACEI/ARB in treating diabetic kidney disease (stage Ⅲ):A meta-analysis and trial sequential analysis

Objective:To evaluate the efficiency of Bushen Huoxue method with ACEI/ARB in treating diabetic kidney disease(stageⅢ).Methods:A total of 8 major electronic databases(CNKI,WanFang,VIP,Sinomed,Pubmed,Embase,Cochrane Liberary,Web of Science)were retrieved since the establishment of the database to October 9,2019.Two reviewers extracted data,and assessed the methodological quality of the included studies.The analysis was made by Stata 15.0 and TSA 0.9 softwares.Results:A total of 10 RCT studies were obtained,including 711 patients with diabetic kidney disease of stageⅢ.Meta-analysis showed that the method of Bushen Huoxue with ACEI/ARB could reduce UAER[WMD=-31.24,95%CI(-42.98,-19.51)],β2-GM[WMD=-92.95,95%CI(-166.05,-19.85)],LDL-C[WMD=-0.19,95%CI(0.19,-0.30)].However,there were no significant effect for HbAlc[WMD=-0.08,95%CI(-0.17,-0.00)],Scr[WMD=-12.96,95%CI(-39.82,13.90)],BUN[WMD=-0.14,95%CI(-0.44,0.17)].The result of TSA indicated that the method of Bushen Huoxue with ACEI/ARB was effective in the treatment of diabetic kidney disease of stageⅢ.Conclusion:The study show that the method of Bushen Huoxue with ACEI/ARB can reduce urinary protein,renal tubular injury and LDL-C in patients with diabetic kidney disease of stageⅢ,and had no effect on HbAlc and renal function.But the conclusion of this study needs further research of high quality.

Unresectable stage Ⅲ non-small-cell lung cancer: Have we made any progress?

Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanceddisease in patients with good performance status consists of combined modality therapy in particular concurrent chemoradiotherapy. But despite a lot of efforts done in the past, local control and survival of patients with unresectable stage Ⅲ non-small-cell lung cancer(NSCLC) remains poor. Improving outcomes for patients with unresectable stage Ⅲ NSCLC has therefore been an area of ongoing research. Research has focused on improving systemic therapy, improving radiation therapy or adding a maintenance therapy to consolidate the initial therapy. Also implementation of newer targeted therapies and immunotherapy has been investigated as well as the option of prophylactic cranial irradiation. This article reviews the latest literature on improving local control and preventing distant metastases. It seems that we have reached a plateau with conventional chemotherapy. Radiotherapy dose escalation did not improve outcome although increasing radiation dose-intensity with new radiotherapy techniques and the use of newer agents, e.g., immunotherapy might be promising. In the future well-designed clinical trials are necessary to prove those promising results.

血清NOX4 MUC1表达水平与Ⅲ期非小细胞肺癌患者放疗疗效及随访1年总生存率的关系研究

目的:研究血清还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4(NOX4)、黏蛋白1(MUC1)表达水平与Ⅲ期非小细胞肺癌(NSCLC)患者放疗疗效及随访1年总生存率的关系。方法:选取2020年4月至2023年3月我院收治的102例Ⅲ期NSCLC患者,均进行放疗干预,并在放疗前检测血清NOX4、MUC1水平,另选择51例健康志愿者作为对照,比较两组血清NOX4、MUC1水平,以及放疗前不同临床特征的Ⅲ期NSCLC患者血清NOX4、MUC1水平。根据放疗效果将Ⅲ期NSCLC患者分为疗效良好组和疗效不佳组,对比两组血清NOX4、MUC1水平。所有患者均进行随访,以中位血清NOX4、MUC1水平为界,比较不同血清NOX4、MUC1水平的患者1年总生存率,并采用单因素和多因素Cox回归分析Ⅲ期NSCLC患者1年生存的影响因素。结果:NSCLC组血清NOX4、MUC1水平均高于对照组(P<0.05)。放疗前不同性别、年龄、体质指数(BMI)、肿瘤位置、肿瘤最大直径、病理分型的Ⅲ期NSCLC患者血清NOX4、MUC1水平比较差异均无统计学意义(P>0.05)。本次102例Ⅲ期NSCLC患者放疗结果显示,疗效良好组例数为55例,疗效不佳组例数为47例。疗效良好组血清NOX4、MUC1水平低于疗效不佳组(P<0.05)。高水平NOX4组患者1年总生存率低于低水平NOX4组(P<0.05),高水平MUC1组患者1年总生存率低于低水平MUC1组(P<0.05)。单因素和多因素Cox回归分析结果显示,血清NOX4、MUC1水平是Ⅲ期NSCLC患者放疗后1年生存的影响因素(P<0.05)。结论:Ⅲ期NSCLC患者血清NOX4、MUC1表达水平与其放疗疗效及随访1年总生存率有关,检测血清NOX4、MUC1水平有利于辅助评估患者放疗疗效和早期预后生存情况。

The famous Chinese medicine doctor Xue Jing-Dong Taohong Siwu Decoction cured 1 case of primary liver cancer stage Ⅲa

Primary liver cancer is the most common malignant tumor of the liver.Surgery,intervention,radiotherapy,and chemotherapy are the main treatment methods in the early stage,and the basic principles of post-treatment are palliative treatment and symptomatic treatment.Xue Jing-Dong,a famous Chinese doctor,started from the etiology and pathogenesis of liver cancer,used the methods of promoting blood circulation to remove blood stasis,nourishing blood and replenishing liver,and applied Taohong Siwu Decoction based on long-term clinical experience to cure 1 case of primary liver cancer stage Ⅲa in two years.The patient’s survival period can be prolonged and the quality of life can be improved.The author begins with the diagnosis of stage Ⅲa liver cancer,western medicine treatment methods,and previous treatment experience of traditional Chinese medicine,and briefly describes the diagnosis and treatment of this patient.

Prognostic and predictive significance of MSI in stages Ⅱ/Ⅲ colon cancer

In colon cancer,classic disease staging remains the key prognosis and treatment determinant.Although adjuvant chemotherapy has an established role in stageⅢcolon cancer patients,in stageⅡit is still a subject of controversy due to its restriction to a small subgroup of patients with high-risk histopathologic features.Patients with stageⅡtumors form a highly heterogeneous group,with five-year relative overall survival rates ranging from 87.5%(ⅡA)to 58.4%(ⅡC).Identifying those for whom adjuvant chemotherapy would be appropriate and necessary has been challenging,and prognostic markers which could serve in the selection of patients more likely to recur or benefit from adjuvant chemotherapy are eagerly needed.The stronger candidate in this category seems to be microsatellite instability(MSI).The recently reported European Society for Medical Oncology guidelines suggest that MSI should be evaluated in stageⅡcolorectal cancer patients in order to contribute in treatment decisionmaking regarding chemotherapy administration.Thehypothetical predictive role of MSI regarding its response to 5-fluorouracil-based adjuvant chemotherapy has proven a much more difficult issue to address.Almost every possible relation between MSI and chemotherapy outcome has been described in the adjuvant colon cancer setting in the international literature,and the matter is far from being settled.In this current report we critically evaluate the prognostic and predictive impact of MSI status in patients with stageⅡand stageⅢcolon cancer patients.

Macroscopic appearance of TypeⅣand giant Type Ⅲ is a high risk for a poor prognosis in pathological stage Ⅱ/Ⅲ advanced gastric cancer with postoperative adjuvant chemotherapy

AIM To evaluate whether a high risk macroscopic appearance(Type Ⅳ and giant Type Ⅲ) is associated with a dismal prognosis after curative surgery, because its prognostic relevance remains elusive in pathological stage Ⅱ/Ⅲ(p Stage Ⅱ/Ⅲ) gastric cancer.METHODS One hundred and seventy-two advanced gastric cancer(defined as pT2 or beyond) patients with p Stage Ⅱ/Ⅲ who underwent curative surgery plus adjuvant S1 chemotherapy were evaluated, and the prognostic relevance of a high-risk macroscopic appearance was examined. RESULTS Advanced gastric cancers with a high-risk macroscopic appearance were retrospectively identified by preoperative recorded images. A high-risk macroscopic appearance showed a significantly worse relapse free survival(RFS)(35.7%) and overall survival(OS)(34%) than an average risk appearance(P = 0.0003 and P < 0.0001, respectively). A high-risk macroscopic appearance was significantly associated with the 13^(th) Japanese Gastric Cancer Association(JGCA) pT(P = 0.01), but not with the 13^(th) JGCA pN. On univariate analysis for RFS and OS, prognostic factors included 13^(th) JGCA p Stage(P < 0.0001)and other clinicopathological factors including macroscopic appearance. A multivariate Cox proportional hazards model for univariate prognostic factors identified highrisk macroscopic appearance(P = 0.036, HR = 2.29 for RFS and P = 0.021, HR = 2.74 for OS) as an independent prognostic indicator. CONCLUSION A high-risk macroscopic appearance was associated with a poor prognosis, and it could be a prognostic factor independent of 13^(th) JGCA stage in p Stage Ⅱ/Ⅲ advanced gastric cancer.

中药联合免疫检查点抑制剂治疗Ⅲ-Ⅳ期非小细胞肺癌的安全性观察

【目的】分析中药联合免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗Ⅲ-Ⅳ期非小细胞肺癌(non-small cell lung cancer,NSCLC)的安全性,探讨ICIs治疗Ⅲ-Ⅳ期NSCLC发生免疫相关不良事件(immune-related adverse events,irAEs)的影响因素。【方法】回顾性分析2019年9月1日至2022年8月31日在广东省中医院大学城医院肿瘤科确诊为Ⅲ-Ⅳ期NSCLC并接受中药联合ICIs治疗的住院患者的中医证型分布、相关用药信息以及irAEs发生情况等,并进行不良反应级别及可能的影响因素分析。【结果】(1)90例NSCLC患者共涉及ICIs单药、ICIs联合化疗、ICIs联合抗血管生成药物、ICIs联合化疗及抗血管生成药物4种治疗方案,其中以ICIs联合化疗及抗血管生成药物的治疗例数最多(52例,49.1%);共使用8种不同的ICIs药物,其中以替雷利珠单抗占比最高(43例,40.6%)。(2)将所有患者分为气虚痰瘀证、痰瘀阻络证、气阴两虚证、气血亏虚证、痰热蕴结证5种证型,其中以气虚痰瘀证为最多(80例,88.9%)。(3)irAEs总体发生率为38.9%(35/90),其中发生G3及以上irAEs的患者仅占5.6%(5/90)。初次发生irAEs的免疫治疗疗程主要集中在1~3程(17例,48.6%)。ICIs单药治疗的患者出现G3及以上irAEs发生率高于联合治疗(33.3%vs 3.6%)。(4)美国东部肿瘤协作组的功能状态(performence status,PS)评分为0~1分(OR=8.218,95%CI:1.607-42.023,P=0.011)和有肾上腺转移(OR=4.497,95%CI:1.237-16.354,P=0.022)是ICIs治疗Ⅲ-Ⅳ期NSCLC发生irAEs的独立危险因素(均P<0.05)。【结论】中药有降低ICIs治疗Ⅲ-Ⅳ期NSCLC不良反应的潜在可能;PS评分为0~1分和有肾上腺转移可能是ICIs治疗Ⅲ-Ⅳ期NSCLC发生irAEs的独立危险因素。

新辅助PD-1抑制剂联合化疗与新辅助化疗治疗可切除Ⅲ期非小细胞肺癌的疗效比较

目的:比较新辅助PD-1抑制剂联合化疗与新辅助化疗治疗可切除Ⅲ期非小细胞肺癌(non-small cell lung cancer,NSCLC)的有效性与安全性,并探讨CD8^(+)和CD103^(+)肿瘤浸润淋巴细胞(tumor-infiltrating lymphocyte,TIL)在新辅助治疗中的作用。方法:回顾性分析2018年08月至2022年03月期间我院诊断为Ⅲ期NSCLC接受新辅助PD-1抑制剂联合化疗(PD-1+化疗组18例)或新辅助化疗(化疗组19例)治疗后进行手术的患者临床资料。比较两组的无病生存期(diseasefree survival,DFS)、客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、病理缓解率以及药物相关不良反应。同时我们使用免疫组化实验技术检测接受新辅助PD-1抑制剂联合化疗方案患者的肺组织(MPR 6例,non-MPR 6例)中CD8^(+)和CD103^(+)TIL的数量,并分析其与疗效的相关性。结果:截至统计时间,PD-1+化疗组仅收集到1名患者出现疾病复发,因此还无法评估该组的中位DFS,化疗组收集到10名患者出现疾病复发,中位DFS为19.1个月。术前影像学评估,PD-1+化疗组ORR为83.3%,高于化疗组的52.6%,差异有统计学意义(P=0.046)。术后病理结果显示,PD-1+化疗组6名患者出现主要病理缓解(major pathological response,MPR),其中4名患者为病理完全缓解(pathological complete response,PCR),化疗组无病理缓解的患者,差异有统计学意义(P=0.021)。PD-1+化疗组不良反应发生率略高于化疗组,差异无统计学意义(P=0.138)。在免疫组化分析中,MPR患者手术切除的组织中CD8^(+)TIL、CD103^(+)TIL数量明显高于治疗前穿刺组织。与非MPR患者相比,MPR患者手术切除的组织中CD8^(+)TIL、CD103^(+)TIL数量更多。结论:相比新辅助化疗,新辅助PD-1抑制剂联合化疗治疗可切除Ⅲ期NSCLC具有更显著的疗效,可以明显提高患者的ORR、MPR以及PCR。CD8^(+)TIL、CD103^(+)TIL数量的动态改变,可能决定可切除Ⅲ期NSCLC患者接受新辅助PD-1抑制剂联合化疗治疗后的病理反应。

Effect of TCM Combined with Chemotherapy on Immune Function and Quality of Life of Patients with Non-small Cell Lung Cancer inStage Ⅲ-Ⅳ

Objective: To observe and compare the effect of traditional Chinese medicine (TCM) combined with chemotherapy (CT) on immune function and quality of life (QOL)of patients with non-small cell lung cancer (NSCLC) in stage Ⅲ-Ⅳ. Methods: One hundred cases with stage Ⅲ-Ⅳ NSCLC were randomly divided into two groups. The treated group (n=50) received CT combined with TCM, and the control group received CT alone. The percentage of T lymphocyte subset in peripheral blood and the change of natural killer (NK) cell count were observed after treatment. The QOL and tolerance of CT were also compared between the two groups after treatment. Results: In the treated group, CD3 cell count, CD4 cell count, CD4/ CDg ratio and NK cell activity were higher than those in control group, while CD8 cell count in the treated group was lower than that in the control group (P<0.05), and QOL and tolerance of CT in the treated group were also better (P<0.05). Conclusion: TCM combined with CT could raise the patients' ability in tolerating CT in stage Ⅲ-ⅣNSCLC.

Role of radiation therapy in the management of stage Ⅲ non-small cell lung cancers: current status and controversies

The treatment of stage Ⅲ non-small cell lung cancer(NSCLC) consisting of the heterogeneous stage subsets remains a challenge. Overall, it has been gradually recognized that radiation therapy(RT) plays a crucial role in the management of stage Ⅲ NSCLC. One superior sulcus tumors are the subset for which the trimodality treatments are clearly preferred. One subset of stage Ⅲ NSCLC has a minimal disease burden with microscopic p N2 disease or with discrete p N2 involvement identified preoperatively, thus technically could undergo a surgical resection. For the incidentally found p N2 disease after complete surgery(ⅢA-1, ⅢA-2), the value of postoperative radiotherapy(PORT) has been recognized by a reassessment based on new data. However, doubt persists regarding how to define the clinical target volume for PORT. For the discrete p N2 involvement identified preoperatively(a selected part of ⅢA-3), induction chemoradiation therapy(CRT) before surgery may yield a survival advantage, although the phase Ⅲ randomized trials in this issue are not conclusive. The other major subset of stage Ⅲ NSCLC is the infiltrative stage Ⅲ NSCLC with N2 or N3 nodal disease(ⅢA-3, ⅢA-4, and ⅢB), for which concurrent CRT is considered as the current standard of care. The potential role of radiation dose escalation/acceleration has been proposed; however, the optimal dose fractionation remains an important unresolved question. Additionally, the role of prophylactic cranial irradiation for stage Ⅲ patients with high risk of brain metastasis is worth of further assessment. Moreover, how to integrate molecular targeted therapy with RT, as well as whether they had a role in stage Ⅲ diseases, are other controversies actively under study in ongoing trials. This review specifically describes the updated role of RT in multimodal approach to treat stage Ⅲ NSCLC and the controversies regarding these results in various situations.

Ⅲ/Ⅳ期结直肠癌肿瘤微环境预后机器学习模型及其在单细胞RNA测序中的应用

Ⅲ/Ⅳ期结直肠癌(CRC)现有治疗方法有限,肿瘤微环境(TME)在其恶性进展和免疫治疗中起关键作用。基于TCGA(the cancer genome attas)数据,采用NMF(non-negative matrix factorization)方法对TME相关基因进行免疫亚型分类,分析不同亚型的TME特征。通过WGCNA(weighted gene co-expression network analysis)方法识别特征基因模块,并整合10种机器学习算法及101种组合,选取最优模型作为CRC患者的TME预后模型。将该模型应用于scRNA-seq数据,揭示高低风险组在功能分析、细胞通信和免疫治疗方面的差异。结果显示,Ⅲ/Ⅳ期CRC样本分为4种免疫亚型,其中C4亚型预后和免疫浸润最差。基于关键基因构建的TME风险模型在训练集和外部验证集上表现良好,揭示高风险肠上皮细胞亚群在TME相关通路的活跃性及药物获益增加。本研究揭示了显著的肿瘤内异质性,并为治疗提供了参考。

益气活血方治疗气阴两虚夹瘀型糖尿病肾病Ⅲ期疗效及对VEGF、TGF-β1的影响

目的:观察益气活血方治疗糖尿病肾病(DN)Ⅲ期属气阴两虚夹瘀型患者的疗效及对血管内皮生长因子(VEGF)、转化生长因子-β(TGF-β1)的影响。方法:选取2018年09月~2019年12月在江西中医药大学附属医院内分泌科就诊的气阴两虚夹瘀型DNⅢ期患者60例为研究对象,分为观察组和对照组各30例。两组均参照指南及专家共识进行DN的一般治疗(降糖、降压、调脂等),对照组予胰激肽原酶肠溶片口服,一次120 U,每日3次,观察组予中药益气活血方加减口服,每日1剂,分早晚2次服用;两组均连续干预8周。检测患者治疗前后血FPG、PBG、HbA1c、β2-MG、BUN、SCr、VEGF、TGF-β1及尿液mALB、UACR水平,并计算两组治疗前后eGFR;观察两组中医证候积分变化,比较其临床疗效。结果:治疗8周后,两组临床总有效率比较,差异具有统计学意义(P<0.05);观察组中医证候积分较治疗前及对照组均明显降低(P<0.05);观察组FPG、HbA1c、PPG、mALB、β2-MG、UACR、VEGF、TGF-β1水平均较对照组明显降低,差异具有统计学意义(P<0.05),观察组SCr、BUN水平较治疗前有所下降,eGFR较治疗有所上升,差异无统计学意义(P>0.05)。结论:益气活血方治疗DNⅢ期属气阴两虚夹瘀型患者,不仅有助于血糖水平的降低,中医证候的改善,而且能减轻早期肾功能损伤,减少尿微量白蛋白,延缓肾功能的进一步恶化,同时具有较好的安全性,其机制可能与降低VEGF、TGF-β1水平,从而延缓肾小管间质瘢痕纤维化及抑制肾小球毛细血管硬化有关。

2型糖尿病肾病Ⅲ期患者气阴两虚、瘀毒互结证与内皮细胞功能障碍相关性分析

目的分析2型糖尿病肾病Ⅲ期患者气阴两虚、瘀毒互结证与内皮细胞功能障碍的相关性,为糖尿病肾病早期肾脏损伤的中医辨证提供一定的客观化依据。方法选取2020年10月至2021年4月湖南中医药大学第一附属医院内分泌、肾病门诊及住院就诊的病人,符合纳入标准的2型糖尿病肾病Ⅲ期气阴两虚、瘀毒互结证患者20例,2型糖尿病患者20例,检测两组患者内皮细胞功能障碍相关性指标,并分析两组各项指标的差异。结果两组患者内皮细胞功能障碍相关指标比较,2型糖尿病肾病Ⅲ期气阴两虚、瘀毒互结证组血管内皮生长因子(vascular endothelial growth factor, VEGF)、内皮素-1(endothelin-1, ET-1)均较2型糖尿病组升高,差异有统计学意义(P<0.05),内皮型一氧化氮合酶(endothelial nitric oxide synthase, eNOS)及一氧化氮(nitric oxide, NO)较2型糖尿病组稍有下降,但差异无统计学意义(P>0.05),血管内皮细胞钙粘连蛋白(VE-cadherin)、神经型钙粘连蛋白(N-cadherin)较2型糖尿病组表达下降,差异有统计学意义(P<0.05)。内皮细胞功能障碍相关指标与尿微量白蛋白/肌酐比值(urine albumin-to-creatinine ratio, UACR)相关性分析结果显示,UACR与VEGF(r=0.921)、UACR与ET-1(r=0.852)、UACR与VE-cadherin(r=0.918)、UACR与N-cadherin(r=0.884)具有相关性(P<0.05)。而UACR与eNOS(r=0.271)、UACR与NO(r=0.731)无明显相关性。结论内皮细胞功能障碍且血清学指标变化可能是早期肾损害的敏感指标;内皮细胞功能障碍与中医气阴两虚、瘀毒互结证之间可能存在一定的相关性,可以作为客观辨识2型糖尿病肾病Ⅲ期气阴两虚、瘀毒互结证的部分生物学基础及依据。

芪藿复方合剂联合西药治疗糖尿病肾病Ⅲ期临床研究

目的观察芪藿复方合剂治疗脾肾气虚型早期糖尿病肾病(diabetic nephropathy,DN)Ⅲ期的临床疗效。方法将60例脾肾气虚型DNⅢ期患者随机分为治疗组和对照组,每组30例。对照组给予降血糖、降血压等对症处理,治疗组加用芪藿复方合剂治疗,疗程3个月。观察两组治疗前后24h尿微量蛋白(urinary microalbumin,UmAlb)、24h尿微量蛋白排泄率(urinary albumin excretion rate,UAER)、血清肌酐(serum creatinine,SCr)、血尿素氮(blood urine nitrogen,BUN)、空腹血糖(fasting blood glucose,FBG)、总胆固醇(total cholesterol,TC)、三酰甘油(triglycerides,TG)、C反应蛋白(C-reactive protein,CRP)及中医证候积分的变化。结果治疗组临床疗效显著优于对照组(P<0.05),治疗组总有效率显著高于对照组(83.3%vs 60.0%,P<0.05);治疗组在降低中医证候积分、FBG、TC、TG、CRP、SCr、24hUmAlb和24h UAER方面显著优于对照组。结论芪藿复方合剂对DN有一定的干预作用,可延缓DN的发展。

非道路用柴油机实现国Ⅲ排放的技术路线研究

为满足国家日益严格控制环境污染的政策要求,并维护公众身体健康,通过分析我国非道路排放标准的发展历程,比较各阶段排气污染物的限值,并进行一系列试验,探究各功率段非道路移动机械用柴油机能够实现非道路国Ⅲ标准的主要技术路线。非道路移动机械用柴油机通过机体优化设计、采用电控EGR、增压中冷、高压共轨等技术路线,即可达到非道路国Ⅲ标准的要求。

外用rb-bFGF辅助治疗骶尾部Ⅲ-Ⅳ期压疮疗效观察

目的:探讨重组牛碱性成纤维细胞生长因子(Recombinant bovine basic fibroblast growth factor,rb-bFGF)凝胶辅助治疗骶尾部Ⅲ-Ⅳ期压疮的临床疗效。方法:纳入2018年1月-2019年12月收治的102例骶尾部Ⅲ-Ⅳ期压疮患者作为研究对象,采用随机数表法分为观察组和对照组,每组各51例。对照组予以常规压疮治疗,观察组在对照组基础上增加应用rb-bFGF外用凝胶。比较两组临床疗效、恢复情况(创面治愈时间、创面肉芽生长时间、换药次数、渗液消失时间),治疗前、治疗1周、2周时均评估创面恢复情况[压疮愈合量表(Pressure ulcer scale for healing,PUSH)]、炎性因子水平[白介素-6(Interleukin-6,IL-6)、肿瘤坏死因子α(Tumor necrosis factorα,TNF-α)、白介素-8(Interleukin-8,IL-8)],记录两组患者创面愈合满意度。结果:治疗2周后,观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组创面治愈时间、创面肉芽生长时间、换药次数、渗液消失时间均小于对照组,差异有统计学意义(P<0.05)。治疗1周、2周时,两组PUSH评分、IL-6、TNF-α、IL-8均呈持续下降趋势,观察组降幅大于对照组,不同治疗方案指标与时间存在交互效应,差异均有统计学意义(P<0.05)。观察组满意度优良率高于对照组,差异有统计学意义(P<0.05)。结论:rb-bFGF外用凝胶辅助治疗骶尾部Ⅲ-Ⅳ期压疮效果良好,有临床应用价值。

支气管动脉灌注化疗加手术治疗Ⅲ期非小细胞肺癌

目的 探讨支气管动脉灌注 (BAI)化疗加手术治疗 期非小细胞肺癌 (NSCL C)的临床应用价值。方法74例 A B期 NSCL C患者随机分为两组 ;BAI化疗组 36例 ,先接受 1～ 3个疗程的 BAI化疗后再手术。对照组 38例 ,确诊后直接手术。观察两组患者的手术切除率。结果 BAI化疗的有效率 (CR+PR)为 5 5 .6 %。 BAI化疗组患者的手术切除率 (94 .4 % )和根治性切除率 (6 1.8% ) ,明显高于对照组 (分别为 6 0 .4 %和 34.6 % ,p<0 .0 5 )。结论 期 NSCL C患者术前进行 BAI化疗可明显提高切除率 。

超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌疗效及病灶无进展生存时间分析

目的:分析超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌(PLC)疗效及病灶无进展生存时间。方法:随机选择医院2020年8月至2021年8月诊治的122例Ⅲ~Ⅳ期PLC患者,根据入院顺序不同分为对照组60例和观察组62例。对照组接受经肝动脉的化疗栓塞相关治疗,观察组实施超声引导下微波介入治疗。比较两组血清肿瘤标志物水平、临床疗效、病灶无进展生存时间、生活质量、并发症及不良反应。结果:治疗后,两组癌胚抗原(CEA)、甲胎蛋白(AFP)水平较治疗前下降,且观察组低于对照组(P<0.05);两组治疗后天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转肽酶(GGT)、碱性磷酸酯酶(ALP)和总胆红素(TBil)均低于治疗前,直接胆红素(DBil)高于治疗前,差异有统计学意义(P<0.05),但两组治疗后数据对比,差异无统计学意义(P>0.05);两组治疗后视觉模拟法评分(VAS)较治疗前下降,且观察组低于对照组(P<0.05);观察组完全缓解率高于对照组(P<0.05),局部残留率和转移复发率低于对照组(P<0.05);观察组病灶无进展生存时间长于对照组(P<0.05);两组治疗后生活质量评分上升,且观察组高于对照组(P<0.05);观察组并发症发生率低于对照组(P<0.05),不良反应发生率低于对照组(P<0.05)。结论:超声引导下微波介入治疗Ⅲ~Ⅳ期PLC能明显提升疗效,延长病灶无进展生存时间,改善其日常的生活质量。